Show Me the Money! Process Modeling in Pharma from the Investor’s Point of View

Process modeling in pharma is gradually gaining momentum in process development but budget restrictions are growing. We first examine whether and how current practices rationalize within a decision process framework with a fictitious investor facing a decision problem subject to incomplete information. We then develop an algorithmic procedure for investment evaluation on both monetary and diffusion-of-innovation fronts. Our methodology builds upon discounted cash flow analysis and Bayesian inference and utilizes the Rogers diffusion of innovation paradigm for computing lower expected returns. We also introduce a set of intangible metrics for quantifying the level of diffusion of process modeling within an organization.

[1]  Eric David,et al.  Pharmaceutical R&D: the road to positive returns , 2009, Nature Reviews Drug Discovery.

[2]  Joan M. Smith A Business Case for Using Modeling and Simulation in Developmental Testing , 2001 .

[3]  San Kiang,et al.  Can pharmaceutical process development become high tech , 2006 .

[4]  Hiroshi Nakagawa,et al.  Decision Support Method for the Choice between Batch and Continuous Technologies in Solid Drug Product Manufacturing , 2018 .

[5]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[6]  Fernando J. Muzzio,et al.  Pharmaceutical engineering science—New approaches to pharmaceutical development and manufacturing , 2010 .

[7]  Sharmista Chatterjee,et al.  An Overview of the Role of Mathematical Models in Implementation of Quality by Design Paradigm for Drug Development and Manufacture , 2017 .

[8]  Gordon Grant,et al.  Building a Business Case for Modeling and Simulation , 2000 .

[9]  Steve Gordon,et al.  Calculating Return on Investment for U.S. Department of Defense Modeling and Simulation , 2011 .

[10]  Troy Shinbrot,et al.  Powder technology in the pharmaceutical industry: the need to catch up fast , 2002 .

[11]  Krist V. Gernaey,et al.  Introducing mechanistic models in Process Analytical Technology education. , 2009, Biotechnology journal.

[12]  Alexandros Koulouris,et al.  The Role of Process Simulation in Pharmaceutical Process Development and Product Commercialization , 2002 .

[13]  J. Strube,et al.  Accelerating Biologics Manufacturing by Upstream Process Modelling , 2019, Processes.

[14]  Marianthi G. Ierapetritou,et al.  Dynamic Flowsheet Model Development and Sensitivity Analysis of a Continuous Pharmaceutical Tablet Manufacturing Process Using the Wet Granulation Route , 2019, Processes.

[15]  Henry G. Grabowski,et al.  A New Look at the Returns and Risks to Pharmaceutical R&D , 1990 .

[16]  John R. Carter A Business Case for Modeling and Simulation , 2001 .

[17]  Konrad Hungerbühler,et al.  Data-driven tiered procedure for enhancing yield in drug product manufacturing , 2016, Comput. Chem. Eng..

[18]  T. De Beer,et al.  Mechanistic modelling of infrared mediated energy transfer during the primary drying step of a continuous freeze‐drying process , 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[19]  Eli Feinerman,et al.  Risk and Probability Premiums for CARA Utility Functions , 1993 .

[20]  Kerry Back,et al.  Asset Pricing and Portfolio Choice Theory , 2010 .

[21]  Blake Johnson,et al.  A Practical Method for Valuing Real Options: The Boeing Approach , 2007 .

[22]  Salvador García-Muñoz,et al.  Definition of Design Spaces Using Mechanistic Models and Geometric Projections of Probability Maps , 2015 .

[23]  Hirokazu Sugiyama,et al.  Uncertainty‐conscious methodology for process performance assessment in biopharmaceutical drug product manufacturing , 2018 .

[25]  Marianthi G. Ierapetritou,et al.  Challenges and opportunities in modeling pharmaceutical manufacturing processes , 2015, Comput. Chem. Eng..

[26]  J. Rantanen,et al.  The Future of Pharmaceutical Manufacturing Sciences , 2015, Journal of pharmaceutical sciences.